Expression of MUC1 and its significance in hepatocellular and cholangiocarcinoma tissue

Shi-Fang Yuan, Kai-Zong Li, Ling Wang, Ke-Feng Dou, Zhen Yan, Wei Han, Ying-Qi Zhang

Abstract

AIM: To investigate the relation between MUC1 expression, distribution, and prognosis in hepatocellular and cholangiocarcinoma (HCC and CC) and cirrhotic liver tissues, and their significance in HCC and CC diagnosis.

METHODS: Expression and distribution of MUC1 were examined by immunohistochemical assay with anti-MUC1 mAb in 59 samples of HCC and 37 samples of CC, 20 samples of cirrhotic liver tissues, and 10 samples of normal liver tissues, seeking possible associations between MUC1 positive expression, distribution in HCC and CC (primary liver cancer, PLC) cases and the studied clinical data.

RESULTS: Immunohistochemical analysis of MUC1 expression showed that in the 96 PLC samples, 68 (70.8%) were strong positive, and 6 (6.2%) were weak positive. Only 4 in the 20 cirrhotic liver tissues were found to be weak positive, while no expression of MUC1 was detected in normal liver tissues. Apparently, the high expression rate of MUC1 in PLC tissues was statistically significant in comparison to that in cirrhotic and normal liver tissues. The expressed MUC1 protein, stained in dark brownish or brownish-yellow particles, chiefly localized on the cancer cell membranes or in cytoplasm. In the 68 strong positive samples, 40 were detected on cell membrane and the other 28 were in cytoplasm. In addition, follow-up studies of those PLC cases demonstrated that MUC1 expression on cell membrane or in cytoplasm was closely associated with PLC prognosis. The expression of MUC1 in PLC had little statistical significance in respect of the pathological types and sizes of the tumors, but a strong relationship regarding histological differentiation, metastasis of lymph nodes, portal canal emboli, and post-operational recurrence of the carcinomas. After 3 years of tumor excision, the metastasis rate in MUC1 positive expression group (67.6%) was much higher than that in MUC1 weak expression group (33.3%) and negative expression group (31.8%), and thus the survival rate in MUC1-positive expression group was significantly different from that in weak and negative expression groups.

CONCLUSION: Expression and localization of MUC1 proteins in primary liver carcinomas (PLCs) may act as prognostic markers, and MUC1 molecules might be helpful in differential diagnosis.

© 2005 The WJG Press and Elsevier Inc. All rights reserved.

Key words: MUC1; Primary liver carcinoma; Prognosis; Immunohistochemistry

Yuan SF, Li KZ, Wang L, Dou KF, Yan Z, Han W, Zhang YQ. Expression of MUC1 and its significance in hepatocellular and cholangiocarcinoma tissue. World J Gastroenterol 2005; 11 (30): 4661-4666
http://www.wjgnet.com/1007-9327/11/4661.asp

INTRODUCTION

Primary liver carcinoma (PLC) is one of the most frequent malignant tumors in clinics, and its tendency to invade and metastasize is the paramount reason for high recurrence after excision, greatly affecting the survival rate of PLC suffers. Even with the developments in PLC therapies, the overall effect is far from radical cure on demand[1]. Thus, it is quite necessary and important to explore new approaches for early diagnosis and immunological treatment of PLC.

MUC1, also known as polymorphic epithelial mucin, is a group of glycoproteins with high molecular mass. One important characteristic of MUC1 gene is the polymorphism. The second expressed extron within the MUC1 coding genes contains a variable number of tandem repeats (VNTRs), and every VNTR is composed of a 20-amino acid peptide motif as VTSAPDTRPAVGSTAPPAHG, constituting main antigenic determinants in this region. Usually MUC1 is expressed at a very low level on normal adenocytes, chiefly localized on gland cell surfaces or in gland cavities by excretion, and thus not recognized by the host immune system[2-4]. It has been found that MUC1 is aberrantly expressed in the forms of misglycolization or incomplete
glycolization, in many tumor tissues like breast, stomach, and colon cancers. These abnormal MUC1 molecules reveal new protein epitopes or carbohydrate antigens, distributed all around the cancer cell surface, and may be recognized by the immune system as notable tumor-associated antigens\[5-9\]. As a tumor marker, MUC1 has been applied in breast cancer and other tumors for their diagnosis and biological treatment\[10-13\].

During the process of malignant transformation and invasion of tumor cells, the changes of MUC1 glycolization influence the biological behavior of tumor cells\[14\]. It was also reported that MUC1 positive expression is an important prognostic indicator in breast cancer and other tumor patients\[15-17\]. However, the expression levels of MUC1 in PLC and cirrhotic liver tissues and their correlation with carcinogenesis still remain to be elucidated. In this study, we used immunohistochemical assay to detect MUC1 expression in PLC and cirrhotic liver tissues, and further investigated the potential significance of MUC1 in PLC diagnosis and immunological treatment.

**MATERIALS AND METHODS**

**Clinical data**

Ninety-six paraffin-embedded PLC samples were collected from patients undergoing surgery in our hospital from 1990 to 2001. Hepatocellular carcinoma (HCC) was found in 59 patients, and cholangiocarcinoma (CC) in 37 patients. Sixty-six samples were from male patients and 30 from female patients, aged 35-68 years (averaged 41.5 years). Lymph node metastasis was confirmed by pathological examination. No chemotherapy or radiotherapy was given before tumor excision. In the 20 samples of cirrhotic tissues, 12 were from male patients and 8 female patients, aged 19-70 years (averaged 40.7 years). Ten samples of normal liver tissues from 10 cases of hepatic angiomatosis served as normal controls. All tissue sections were stained with hematoxylin and eosin (H&E).

The diagnosis of HCC was primarily based on history of chronic hepatitis, results of AFP detection, and space occupying lesions in the liver on ultrasonography and CT. The pathological diagnosis of HCC and CC was confirmed by H&E staining of the tissue sections. Patients were regularly examined by ultrasonography and CT after PLC surgery. Tumor recurrence was defined as new focus was detected, and metastasis was defined when lymph nodes of hepatic portal vein became swollen or new foci were found in distal organs.

**Preparation of tissue samples**

For routine sections, tissue samples were immersion-fixed in 40 g/L buffered formaldehyde for hours, and dehydrated through graded alcohols. After paraffin wax embedding, sections of 5 μm thickness were cut and mounted on coated glass slides. Then H&E as well as immunohistochemical staining were performed.

**Immunohistochemical assay**

Endogenous peroxidase blocker and normal house serum were added to all sections for 30-min incubation at room temperature to minimize non-specific staining, and antigen restoration was performed by microwave method. Mouse anti-human MUC1 mAb working at 1:100 dilution was purchased from Antibody Diagnostica Inc., USA, and ABC diagnostic kit was purchased from Santa Cruz, USA. Detection procedures were performed according to the kit instructions. The cover slide was treated with goat anti-mouse bridging antibody (1:200) for 30 min at 37 °C. Finally, diaminobenzidine tetrachloride was used for color development and the slides were counterstained with hematoxylin. Dehydration, clearing, covering, and light microscopy were performed routinely. Blank test and replacement test were set for negative controls.

**Result determination**

Brownish-yellow particles under light microscope were considered positive. Three positive levels according to positive cell percentage in five high power, randomized, observation fields were classified: Level 0: cells without stained particles (negative MUC1 expression, -), Level 1: positive cell percentage less than 25% (weak MUC1 expression, +), and Level 2: positive cell percentage more than 25% (strong MUC1 expression, ++).

**Statistical analysis**

All data were analyzed by SPSS 11.0 (SPSS Inc., USA). Statistical methods included χ²-test, Fisher's exact test, and the Kruskal-Wallis test. P<0.05 was considered statistically significant.

**RESULTS**

**MUC1 expression in primary liver carcinoma, cirrhotic liver, and normal liver tissues**

In the 96 tested PLC samples, 68 were strong positive (Figures 1A and B) and 6 were weak positive. Only 4 in the 20 cirrhotic liver tissues were found to be weak positive (Figure 1C), while no expression of MUC1 was detected in normal liver tissues (Figure 1D). Apparently, the high expression rate of MUC1 in PLC tissues was statistically significant in comparison to that in cirrhotic and normal liver tissues (P<0.05, Table 1).

**Table 1** Expression of MUC1 in PLC, cirrhotic, and normal liver tissues

| Group          | n   | - | +  | ++ |
|----------------|-----|---|----|----|
| Normal liver   | 10  | 10| 0  | 0  |
| Cirrhotic liver| 20  | 16| 4  | 0  |
| PLC            | 96  | 22| 6  | 68*|

*P<0.05 vs cirrhotic and normal liver tissues.

**MUC1 expression was associated with PLC pathology**

MUC1 was both expressed in HCC (Figure 2) and CC tissues with no statistical difference between them (P>0.05), demonstrating that MUC1 gene expression was not associated with histological classification of the hepatic tumors. The
sizes of solid tumors were not different in the MUC1 expression either ($P>0.05$). However, MUC1 expression in well differentiated tumor tissues were significantly different from that in moderately and poorly differentiated tissues ($P<0.05$), and so did in lymph node metastases, portal vein embolism, and 3-year post-operation recurrence ($P<0.05$). The association of MUC1 expression and PLC clinical pathology behavior is illustrated in Table 2.

**Localization of MUC1 in PLC tissues and prognosis**

By immunohistochemical assay, the expressed MUC1 proteins in liver carcinoma tissues were stained as dark brownish or brownish-yellow particles, and mainly localized on the cancer cell membranes (Figure 1A) or in cytoplasm (Figure 1B). Table 3 shows the association of strong MUC1 expression and the prognosis of 68 cases of hepatic tumor.

**MUC1 expression and PLC metastasis**

Three years after surgery, metastasis occurred in 55 out of

| Clinical pathology                        | $n$ | MUC1 expression | $P$  |
|-------------------------------------------|-----|-----------------|------|
| **Histological classification**           |     |                 |      |
| HCC                                       | 59  | 17 4 38         | $>0.05$ |
| CC                                        | 37  | 5 2 30          |      |
| **Histological differentiation**          |     |                 |      |
| Well                                       | 30  | 14 2 14         | $<0.01$ |
| Moderate                                   | 40  | 6 2 32          |      |
| Poor                                       | 26  | 2 2 22          |      |
| **Lymph node metastasis**                 |     |                 |      |
| Yes                                        | 52  | 5 2 45          | $<0.01$ |
| No                                         | 44  | 17 4 23         |      |
| **Portal vein embolism**                  |     |                 |      |
| Yes                                        | 32  | 1 2 29          | $<0.01$ |
| No                                         | 64  | 21 4 39         |      |
| **Size of solid tumor (cm)**              |     |                 |      |
| <5                                         | 49  | 15 2 32         | $>0.05$ |
| $\geqslant 5$                              | 47  | 7 4 36          |      |
| **Recurrence (3 yr)**                     |     |                 |      |
| Yes                                        | 65  | 9 4 52          | $<0.01$ |
| No                                         | 31  | 13 2 16         |      |

$^aP<0.05$ vs moderately differentiated HCC. $^bP<0.05$ vs poorly differentiated HCC.

Table 3 shows the association of strong MUC1 expression and the prognosis of 68 cases of hepatic tumor.
the 96 PLC patients: intra-hepatic metastasis in 30 cases, pulmonary metastasis in 12 cases, osseous metastasis in 4 cases, and lymph node metastasis in 9 cases. The metastasis rate in MUC1 strong positive expression group (67.6%) was much higher than that in MUC1 negative expression group (31.8%, P<0.01, Table 4).

Table 3 MUC1 localization in PLC tissues and prognosis of PLC

| Clinical pathology            | n  | MUC1 expression | P   |
|-------------------------------|----|-----------------|-----|
|                               |    | Membrane | Cytoplasm |
| Lymph node metastasis         |    |           |          |
| Yes                           | 45 | 23       | 22      | <0.05 |
| No                            | 23 | 17       | 6       |
| Portal vein embolism          |    |           |          |
| Yes                           | 29 | 11       | 18      | <0.01 |
| No                            | 29 | 9        | 10      |
| Survival rate (yr)            |    |           |          |
| <3                            | 50 | 17       | 33      | <0.01 |
| ≥3                            | 18 | 13       | 5       |

Table 4 MUC1 expression and post-operation metastasis

| MUC1 expression | n    | Rate of metastasis (%) |
|-----------------|------|------------------------|
| Negative        | 22   | 31.8                   |
| Weak positive   | 6    | 33.3                   |
| Strong positive | 68   | 67.6                   |

*P<0.01 vs negative.

Positive MUC1 expression in PLC tissues and survival rate

Follow-up data were collected from 86 of the 96 PLC patients (89.6%). The survival rate in MUC1 strong positive expression group was significantly different from that in MUC1 weak positive or negative expression group (P<0.05, Table 5).

Table 5 Positive MUC1 expression in PLC tissues and survival of PLC patients

| MUC1 expression | n  | Survival rate (%) |
|-----------------|----|-------------------|
|                 |    | 6 mo | 12 mo | 24 mo | 36 mo |
| Negative        | 22 | 86.4 | 72.7  | 59.1  | 50.0  |
| Weak positive   | 6  | 50.0 | 33.3  | 33.3  | 33.3  |
| Strong positive | 68 | 51.5 | 44.1  | 29.4  | 26.4  |

*P<0.05 vs negative.

DISCUSSION

To investigate the possible correlation among MUC1 expression and localization and prognosis in PLC and cirrhotic liver tissues, we carried out immunohistochemical assay to detect the MUC1 expression in 96 samples of PLC hepatic tissues. The results showed that MUC1 was strongly expressed on PLC cell membrane or in cytoplasm, while weak and negative expressions were found in human cirrhotic liver tissues, and no expression was found in normal liver tissues. The difference was of statistical significance. In addition, MUC1 expression increased during the process of transformation from benign cells to malignant cells, which is in accordance with the common understanding of hepatic carcinoma resulting from liver cirrhosis.

There are discrepant results in reports on MUC1 expression and PLC histological differentiation types. Sasaki and Nakanuma[18] reported that MUC1 core protein is expressed in intrahepatic bile duct carcinoma, but not in HCC. Cao et al.[19], demonstrated that MUC1 is remarkably expressed in HCC cells and can be considered as an indicator of HCC prognosis. In our test, MUC1 expression was not associated with either histological classification or size of the tumors. Based on our testing data, we take it that MUC1 can be used as one of the helping indicators early diagnosis of PLC, by hepatic puncture biopsy before PLC surgery.

In previous studies, it was suggested that high-level MUC1 expression is reversely correlated with prognosis of tumor patients. For example, MUC1 expression is closely related with prognosis of breast cancer sufferers[3,19]. However, possible association(s) of MUC1 expression levels in PLC liver tissues with the prognosis still remains uncertain. From our test results, it is clear that MUC1 expression levels are quite different in well-differentiated tumor tissues and moderately- or poorly-differentiated tumor tissues, and so are the differences among MUC1 expression and lymph node metastasis, portal vein embolism, and post-operation recurrence. Expression and localization of MUC1 proteins in PLC may act as different prognostic markers of PLC. We also found that the prognosis was worse in cytoplasm expression group than in cell surface expression group. It is reasonable to deduce that MUC1 molecule on cell surface may stimulate protective immunities (for instance, specific cytotoxic T lymphocytes) from the body to fight against the tumor cells.

Intra-hepatic tumor invasion in portal vein system with subsequent metastasis is the major cause of morbidity and mortality in patients with PLC. In our work, it was apparent that MUC1 expression was associated with PLC cell infiltration and metastasis as well. The possible mechanisms might be as follows. (1) E-cadherin is a transmembrane glycoprotein that mediates calcium-dependent, inter-cellular adhesion and is specifically involved in epithelial cell-to-cell adhesion. In cancers, decreased E-cadherin expression is one of the alterations that characterize the invasive phenotype, and the data support its role as a tumor suppressor. Studies have shown that aberrant E-cadherin expression is associated with the acquisition of invasiveness and more advanced tumor stage for many cancers including lung cancer, prostate cancer, gastric cancer, and breast cancer, indicating that MUC1 promotes tumor metastasis by downregulating E-cadherin expression and its binding to beta-catenin[21-23]. (2) MUC1 acts as anti-cell adhesion molecules. High density of filamentous MUC1 molecules expressed on tumor cell surface might prevent binding between membrane-anchored ligands and corresponding receptors, minimize intercellular interactions induced by integrin in extracellular matrix, thus facilitating cancer cell invasion[24,25]. (3) Sialyl Lewis epitopes on MUC1 molecules function as
ligands to E-selectin in injured or inflammatory vascular endothelial cells, and facilitate tumor cell adhesion, infiltration, and metastasis\(^2\).

Currently, carcinoma therapy is still one of the major treatments for PLC, but has limitations for PLC patients of life expansion and quality promotion. MUC1 molecules play a double role in tumor genesis and development\(^6\). On one hand, aberrant MUC1 expression influences inter-cellular adhesions via surface molecule interactions, and makes easier for tumor cell growth and metastasis. On the other hand, as a hapten with newly formed glycan or peptide epitopes because of incomplete glycolization, MUC1 induces anti-tumor immune responses, and may be a target for tumor immunotherapy. It was reported that clinical MUC1 vaccination trials for breast cancer are in progress\(^{27\text{-}35}\). We also discovered that MUC1 gene vaccination induces specific cytotoxic T lymphocyte responses in mice\(^{29}\). MUC1-targeted tumor therapeutic vaccination may be effective for PLC treatment.

To conclude, we used immunohistochemical assay to detect MUC1 expression in PLC, cirrhotic and normal liver tissues, and the results show that MUC1 may be an indicator for PLC diagnosis and prognosis. As HCC is common in China\(^{29\text{-}31}\) and most Asian countries\(^{29\text{-}33}\), further investigations on MUC1 roles in PLC genesis and development are of particular significance in providing new ways of PLC treatment.

**REFERENCES**

1. Aoki T, Imamura H, Hasegawa K, Matsukura A, Sano K, Sugawara Y, Kokudo N, Makuchii M. Sequential preoperative arterial and portal venous embolizations in patients with hepatocellular carcinoma. *Arch Surg* 2004; 139: 766-774
2. Croce MV, Isla-Larram MT, Demichelis SO, Gori JR, Price MR, Segal-Eirias A. Tissue and serum MUC1 mucin detection in breast cancer patients. *Breast Cancer Res Treat* 2003; 81: 195-207
3. Rahm J, Dabbagh L, Pasdar M, Hugh JC. The importance of MUC1 cellular localization in patients with breast carcinoma: an immunohistologic study of 71 patients and review of the literature. *Cancer* 2001; 91: 1973-1982
4. von Mensdorff-Pouilly S, Snijdewint FG, Verstraeten AA, Verheijen RH, Kenemans P. Human MUC1 mucin: a multifaceted glycoprotein. *Int J Biol Markers* 2000; 15: 343-356
5. Chu PG, Weiss LM. Immunohistochemical characterization of signet-ring cell carcinomas of the stomach, breast, and colon. *Am J Clin Pathol* 2004; 121: 884-892
6. Baldus SE, Monig SP, Huxel S, Landsberg S, Hanisch FG, Engelmann K, Schneider PM, Thiele J, Holshcer AH, Dienes HP. MUC1 and nuclear beta-catenin are coexpressed at the invasion front of colorectal carcinomas and are both correlated with tumor prognosis. *Clin Cancer Res* 2004; 10: 2790-2796
7. Levine A, Klimstra DS, Adsay NV, Andea A, Basturk O, MUC1 and MUC2 in pancreatic neoplasia. *J Clin Pathol* 2004; 57: 456-462
8. Sakamoto H, Yonezawa S, Utsunomiya T, Tanaka S, Kim YS, Sato E. Mucin antigens expression in gastric carcinomas of young and old adult. *Hum Pathol* 1997; 28: 1056-1065
9. Utsunomiya T, Yonezawa S, Sakamoto H, Kitamura H, Hokita S, Aiko T, Tanaka S, Irimura T, Kim YS, Sato E. Expression of MUC1 and MUC2 mucins in gastric carcinomas: its relationship with the prognosis of the patients. *Clin Cancer Res* 1998; 4: 2605-2614
10. Mukherjee P, Madsen CS, Ginardi AR, Tindner TL, Jacobs F, Parker J, Agrawal B, Longnecker BM, Gendler SJ. Mucin 1-specific immune therapy in a mouse model of spontaneous breast cancer. *J Immunother* 2003; 26: 47-62
11. Chen D, Xia J, Tanaka Y, Chen H, Koido S, Wernet O, Mukherjee P, Gendler SJ, Kufe D, Gong J. Immunotherapy of spontaneous mammary carcinoma with fusions of dendritic cells and mucin 1-positive carcinoma cells. *Immunology* 2003; 109: 300-307
12. Johnen H, Kulbe H, Pecher G. Long-term tumor growth suppression in mice immunized with naked DNA of the human tumor antigen mucin (MUC1). *Cancer Immunol Immunother* 2001; 50: 356-360
13. Snijdewint FG, von Mensdorff-Pouilly S, Karunat-Wanamarta AH, Verstraeten AA, Livingston PO, Hilgers J, Kenemans P. Antibody-dependent cell-mediated cytotoxicity can be induced by MUC1 peptide vaccination of breast cancer patients. *Int J Cancer* 2001; 93: 97-106
14. Byrd JC, Bressaller RS. Mucins and mucin binding proteins in colorectal cancer. *Cancer Metastasis Rev* 2004; 23: 77-99
15. Hiraga Y, Tanaka S, Haruma K, Yoshihara M, Sumii K, Kajiyama G, Shimamoto F, Kohno N. Immunoreactive MUC1 expression at the deepest invasive portion correlates with prognosis of colorectal cancer. *Oncolology* 1998; 55: 307-319
16. Kocer B, Soran A, Kiyak G, Erdogan S, Ergolu A, Bozkurt B, Solak C, Cengiz O. Prognostic significance of mucin expression in gastric carcinoma. *Dig Dis Sci* 2004; 49: 954-964
17. Yonezawa S, Sato E. Expression of mucin antigens in human cancers and its relationship with malignancy potential. *Pathol Int* 1997; 47: 813-830
18. Sasaki M, Nakamura Y. Expression of mucin core protein of mammary type in primary liver cancer. *Hepatology* 1994; 20: 1192-1197
19. Cao Y, Karsten U, Otto G, Bannach P. Expression of MUC1, Thomsen-Friedenreich antigen, Tn, sialosyl-Tn, and alpha2,6-linked sialic acid in hepatocellular carcinomas and preneoplastic hepatocellular lesions. *Virchows Arch* 1999; 434: 503-509
20. Vgenopoulou S, Lazaris AC, Markopoulos C, Boltetsou E, Kyriakou V, Kavantzas N, Patsouris E, Davaris PS. Immunohistochemical evaluation of immune response in invasive ductal breast cancer of not otherwise-specified type. *Breast* 2003; 12: 172-178
21. Fujita K, Kenda D, Yamamoto M, Matsumoto T, Fujime M, Irimura T. Expression of MUC1 mucins inversely correlated with post-surgical survival of renal cell carcinoma patients. *Br J Cancer* 1999; 80: 301-308
22. Wesseling J, Van der Valk SW, Vos HL, Sonnenberg A, Hikens J. Episialin (MUC1) overexpression inhibits integrin-mediated cell adhesion to extracellular matrix components. *J Cell Biol* 1995; 129: 255-265
23. Kondo K, Kohno N, Yokoyama A, Hiwada K. Decreased MUC1 expression induces E-cadherin-mediated cell adhesion of breast cancer cell lines. *Cancer Res* 1998; 58: 204-2019
24. Steealant WF, Goeman J, Philippe J, Oomen LC, Hikens J, Krzewinski-Recchi MA, Huet G, Van der Eycken J, Delannoy P, Bruyneel EA, Mareel MM. Alkyl-lysoospholipid 1-O- octadecyl-2-O-methyl- glycerophosphocholine induces invasion through episialin-mediated neutralization of E-cadherin in human mammary MCF-7 cells in vitro. *Int J Cancer* 2001; 92: 527-536
25. Satoh S, Hinoda Y, Hayashi T, Burdick MD, Imai K, Hollingsworth MA. Enhancement of metastatic properties of pancreatic cancer cells by MUC1 gene encoding an anti-adhesion molecule. *Int J Cancer* 2000; 88: 507-518
26. Takao S, Uchikura K, Yonezawa S, Shinh ci H, Aikou T. Mucin core protein expression in extrahepatic bile duct carcinoma is associated with metastases to the liver and poor prognosis. *Cancer* 1999; 86: 1966-1975
27. Muscelli C, Raguapath G, Gilewski T, Panages AS, Spinat Y, Livingston PO. Reevaluation of the cellular immune response in breast cancer patients vaccinated with MUC1. *Int J Cancer* 2002; 97: 660-667
28 Yuan SF, Li KZ, Wang L, Yan Z, Han W, Zhang YQ. Induction of specific cytotoxic T lymphocytes and humoral immune response by MUC1 DNA vaccine in mice. *Xibao Yu Fenzi Mianyixue Zazhi* 2003; 19: 343-345

29 Yuen MF, Cheng CC, Lauder IJ, Lam SK, Ooi CG, Lai CL. Early detection of hepatocellular carcinoma increases the chance of treatment: Hong Kong experience. *Hepatology* 2000; 31: 330-335

30 Chen TH, Chen CJ, Yen MF, Lu SN, Sun CA, Huang GT, Yang PM, Lee HS, Duffy SW. Ultrasound screening and risk factors for death from hepatocellular carcinoma in a high risk group in Taiwan. *Int J Cancer* 2002; 98: 257-261

31 Yuan SF, Wang L, Li KZ, Yan Z, Han W, Zhang YQ. Inhibitory effect of MUC1 gene immunization on H22 hepatocellular carcinoma growth. *Shijie Huaren Xiaohua Zazhi* 2003; 11: 1322-1325

32 Zhou J, Tang ZY, Fan J, Wu ZQ, Li XM, Liu YK, Liu F, Sun HC, Ye SL. Expression of platelet-derived endothelial cell growth factor and vascular endothelial growth factor in hepatocellular carcinoma and portal vein tumor thrombus. *J Cancer Res Clin Oncol* 2000; 126: 57-61

33 Sun HC, Tang ZY, Li XM, Zhou YN, Sun BR, Ma ZC. Microvessel density of hepatocellular carcinoma: its relationship with prognosis. *J Cancer Res Clin Oncol* 1999; 125: 419-426

34 Shuto T, Hirohashi K, Kubo S, Tanaka H, Yamamoto T, Higaki I, Takemura S, Kinoshita H. Treatment of adrenal metastases after hepatic resection of a hepatocellular carcinoma. *Dig Surg* 2001; 18: 294-297

35 Huang YH, Wu JC, Lui WY, Chan GY, Tsay SH, Chiang JH, King KL, Huo TI, Chang FY, Lee SD. Prospective case-controlled trial of adjuvant chemotherapy after resection of hepatocellular carcinoma. *World J Surg* 2000; 24: 551-555